“We are focused on advancing RLYB116 into a confirmatory pharmacokinetic/pharmacodynamic study this quarter, and believe that data from this study will demonstrate RLYB116’s potential to be a best-in-class therapeutic for patients with complement-driven diseases,” said Stephen Uden, M.D., Chief Executive Officer of Rallybio (RLYB). “Leveraging our team’s deep expertise in the complement field, we are well-positioned to maximize RLYB116’s transformative potential across multiple billion-dollar market opportunities. Additionally, we believe significant value resides within our preclinical pipeline, which includes REV102 and RLYB332. By advancing our innovative pipeline, we are committed to creating exceptional value for our shareholders while delivering life-changing therapies to patients who need them most.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLYB:
- Rallybio downgraded to Hold from Buy at JonesResearch
- Rallybio downgraded to In Line from Outperform at Evercore ISI
- Rallybio downgraded to Neutral from Buy at H.C. Wainwright
- Citizens JMP downgrades Rallybio on RLYB212 discontinuation
- Rallybio downgraded to Market Perform from Outperform at Citizens JMP